News
Public · Published
Pfizer Just Raised Guidance. The Bigger Test Comes Next
Pfizer raised its 2026 forecast after third-quarter profits beat expectations, reporting revenue of $16.6 billion and adjusted earnings of $0.87 per share. It now expects sales of $62 billion to $64 billion and adjusted earnings of $2.95 to $3.05 per share in 2026.
Published:
Updated:
What happened
Pfizer raised its 2026 forecast after third-quarter profits beat expectations, reporting revenue of $16.6 billion and adjusted earnings of $0.87 per share. It now expects sales of $62 billion to $64 billion and adjusted earnings of $2.95 to $3.05 per share in 2026.
Confirmed
Global impact / market context
The higher forecast signals that newer medicines and cost cuts are currently helping offset falling sales of COVID-19 medicines and Prevnar vaccinations. Whether that support lasts matters for revenue and profit as patent expirations and possible U.S. medication-pricing changes create future pressure.
Analyst inference
Pfizer says it is on schedule to achieve nearly all of its targeted $7.2 billion in net savings by the end of 2026 and is seeking another $2.5 billion in cuts for 2027–2029. Those savings could support profits, but the article identifies drug competition and pricing as risks.
Analyst inference
What to watch
- Pfizer's fourth-quarter results may show whether newer medicines continue growing enough to offset declines in COVID-19 medicines and Prevnar vaccinations. Analyst inference
- Management is seeking another $2.5 billion in cuts during 2027–2029; watch for details on whether and how those savings are pursued. Proposed
- Clinical results targeted for 2027 in cancer and obesity could indicate whether these research programs may contribute to future growth. Confirmed